The UK oncolytic virus therapy market is estimated to grow at a CAGR of more than 13% during the forecast period. Research in the field of Oncolytic virus is still in its initial phase in UK. A second-generation oncolytic virus-based drug is registered in UK under the name of talimogene laherparepvec. Amgen Inc, Merck & Co., Inc. and Experimental Cancer Medicine Centre (ECMC) are few of the key organizations which are investing in the clinical trials involving oncolytic virus therapy in UK in collaboration with Cancer Research UK. In line with the strategy of developing treatment alternatives, the companies have introduced various clinical trials including the effect of talimogene laherparepvec on melanoma and head and neck cancers.

Request a Free Report on Sample of UK Oncolytic Virus Therapy Market @ https://www.omrglobal.com/request-sample/uk-oncolytic-virus-therapy-market

The UK oncolytic virus therapy market is segmented on the basis of product and application. Based on the product, the market is segmented into HSV-based oncolytic viruses, adenoviruses-based oncolytic viruses, vaccinia virus-based oncolytic viruses, vesicular stomatitis virus-based oncolytic viruses, Newcastle disease oncolytic viruses, and other oncolytic viruses. HSV-based oncolytic virus therapy held the highest market share of over 94% in 2018, whereas, adenoviruses-based therapy held the rest. Based on the application, the market is segmented into prostate cancer, breast cancer, ovarian cancer, melanoma, and others. In 2018, the melanoma application held the largest market share.

A full Report of UK Oncolytic Virus Therapy Market at https://www.omrglobal.com/industry-reports/uk-oncolytic-virus-therapy-market

The report covers the analysis of several players such as Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Medigene AG, Merck and Co. Inc., Amgen Inc., Orca Therapeutics, OncoTheis, and others operating in the UK oncolytic virus therapy market. PsiOxus Therapeutics Ltd. is one of the companies headquartered in UK. The company is collaborating with other immuno-oncology companies in the market for the purpose of increasing their consumer base. In December 2017, the application for the clinical trial of NG-348 for the treatment of solid tumor was approved. For this, the Bristol Myers Squibb has paid $15 million to PsiOxus as a per the licensing agreement between the two firms. The two companies entered into strategic collaboration on Dec 2016, in which Bristol Myers granted $50 million to PsiOxus.

UK Oncolytic Virus Therapy Market Segmentation

By Product

• HSV-Based Oncolytic Virus
• Adenoviruses-Based Oncolytic Virus
• Vaccinia Virus-Based Oncolytic Virus
• Vesicular Stomatitis Virus-Based Oncolytic Virus
• Newcastle Disease Virus- Based Oncolytic Virus
• Others

By Application

• Prostate Cancer
• Breast Cancer
• Ovarian Cancer
• Melanoma
• Others

Company Profiles

• AbbVie, Inc.
• Amgen, Inc.
• Bristol-Myers Squibb Company
• Cold Genesys Inc.
• Creative Biolabs Inc.
• Cynvec LLC
• DNAtrix Inc.
• Genelux Corp.
• Janssen Biotech Inc.
• Merck & Co., Inc.
• Oncolytic Biotech, Inc.
• Oncorus Inc.
• Sorrento Therapeutics Inc.
• Vyriad

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/uk-oncolytic-virus-therapy-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. AnuragTiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 780-304-0404
Visit for https://www.omrglobal.com/industry-reports/oncolytic-virus-therapy-market